BioSpace News Archive

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced its operating and financial results for the first quarter 2023.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reported financial results for the first quarter ended April 1, 2023.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported first quarter 2023 financial results and provided a corporate update.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, reported financial results for the first quarter of 2023.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and six months ended March 31, 2023.

Rezolute, Inc. announced its financial results for the third quarter of fiscal 2023 ended March 31, 2023.

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.